NURIX THERAPEUTICS, INC. Shareholders' Equity
NURIX THERAPEUTICS, INC. (NRIX) had Shareholders' Equity of $402.63 million as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-09
- 2026-05-31: Stockholders' Equity Attributable to Parent $402.63M.
- 2026-02-28: Stockholders' Equity Attributable to Parent $480.89M.
- 2025-11-30: Stockholders' Equity Attributable to Parent $538.75M.
- 2025-08-31: Stockholders' Equity Attributable to Parent $372.25M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-05-31 | $402.63M 10-Q · filed 2026-07-09 |
| 2026-02-28 | $480.89M 10-Q · filed 2026-07-09 |
| 2025-11-30 | $538.75M 10-Q · filed 2026-07-09 |
| 2025-08-31 | $372.25M 10-Q · filed 2025-10-09 |
| 2025-05-31 | $447.60M 10-Q · filed 2026-07-09 |
| 2025-02-28 | $480.92M 10-Q · filed 2026-07-09 |
| 2024-11-30 | $526.99M 10-Q · filed 2026-07-09 |
| 2024-08-31 | $376.86M 10-Q · filed 2025-10-09 |
| 2024-05-31 | $370.69M 10-Q · filed 2025-10-09 |
| 2024-02-29 | $168.75M 10-Q · filed 2025-10-09 |
| 2023-11-30 | $200.49M 10-K · filed 2026-01-28 |
| 2023-08-31 | $233.82M 10-Q · filed 2024-10-11 |
| 2023-05-31 | $259.92M 10-Q · filed 2024-10-11 |
| 2023-02-28 | $274.05M 10-Q · filed 2024-10-11 |
| 2022-11-30 | $303.70M 10-K · filed 2026-01-28 |
| 2022-08-31 | $342.55M 10-Q · filed 2023-10-12 |
| 2022-05-31 | $266.74M 10-Q · filed 2023-10-12 |
| 2022-02-28 | $305.92M 10-Q · filed 2023-10-12 |
| 2021-11-30 | $342.30M 10-K · filed 2025-01-28 |
| 2021-08-31 | $375.22M 10-Q · filed 2022-10-06 |
| 2021-05-31 | $398.18M 10-Q · filed 2022-10-06 |
| 2021-02-28 | $270.13M 10-Q · filed 2022-10-06 |
| 2020-11-30 | $290.27M 10-K · filed 2023-02-09 |
| 2020-08-31 | $307.62M 10-Q · filed 2021-10-14 |
| 2020-05-31 | -$61.53M 10-Q · filed 2021-10-14 |
| 2020-02-29 | -$69.80M 10-Q · filed 2021-10-14 |
| 2019-11-30 | -$57.71M 10-K · filed 2022-01-28 |
| 2019-08-31 | -$44.44M 10-Q · filed 2020-10-14 |
| 2019-05-31 | -$42.20M 10-Q · filed 2020-10-14 |
| 2019-02-28 | -$39.36M 10-Q · filed 2020-10-14 |
| 2018-11-30 | -$36.85M 10-K · filed 2022-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |